Zobrazeno 1 - 10
of 27
pro vyhledávání: '"de Tute RM"'
Autor:
Charlotte Pawlyn, Alina Striha, Mark T. Drayson, de, Tute, Rm, John R Jones, Walter M Gregory, David A Cairns, Andy C. Rawstron, Martin Kaiser, Graham Jackson, G. J. Morgan, Faith E. Davies, Anna Chalmers, Graham P. Cook, Roger G. Owen, Corinne Collett, Nigel H. Russell
Publikováno v:
British Journal of Haematology. 173:5-178
Autor:
Rawstron, AC, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, K-A, Liptrot, S, O'Brien, D, de Tute, RM, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, AP, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, JL, Stetler-Stevenson, M, Yuan, C, Broome, HE, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, CM, Emerson, R, Robins, HS, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, TJ, Wierda, WG, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P, CLL, ERIC European Res Initiative
Publikováno v:
Leukemia
Leukemia, vol 30, iss 4
Leukemia, 30(4), 929-936. Nature Publishing Group
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Leukemia, vol 30, iss 4
Leukemia, 30(4), 929-936. Nature Publishing Group
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223b87a88cadbba63e43e546bd4fa680
Autor:
Walter M Gregory, AJ Szubert, Gareth J. Morgan, J. A. Child, Andy C. Rawstron, Mark T. Drayson, de, Tute, Rm, Graham Jackson, Roger G. Owen, Faith E. Davies, Gordon Cook, Sue E. Bell
Minimal residual disease (MRD) is a powerful determinant of overall outcome in multiple myeloma (MM). Previous studies have demonstrated that the presence of MRD at the traditional day 100 assessment point following autologous stem cell transplant (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2182f54c65fe37709b4844d357ff2788
https://europepmc.org/articles/PMC4938335/
https://europepmc.org/articles/PMC4938335/
Autor:
R de Tute, Rémi Letestu, Andrew R. Pettitt, Andy C. Rawstron, C Moreno, Ke Lin, Peter Hillmen, Michael Kneba, Neus Villamor, Florence Cymbalista, Jane Shingles, Paolo Ghia, H. Kartsios, Matthias Ritgen, Claudia Fazi, Michael Hallek, Emili Montserrat, S Böttcher
Publikováno v:
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Detection of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) is becoming increasingly important as treatments improve. An internationally harmonised four-colour (CLR) flow cytometry MRD assay is widely used but has limitations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b4e12bf573a7ff0556ff8a7b5d77000
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=10950
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=10950
Autor:
de Tute RM; Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals Trust, Leeds, UK. rdetute@nhs.net., Cook G; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. g.cook@leeds.ac.uk., Cairns DA; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Brown JM; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Cavenagh J; Department of Haematology, Barts & The London NHS Trust, London, UK., Ashcroft AJ; Mid-Yorks NHS Trust, Wakefield, UK., Snowden JA; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust & Department of Endocrinology & Metabolism, University of Sheffield, Sheffield, UK., Yong K; Department of Haematology, University College London, London, UK., Tholouli E; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester Foundation Trust, Manchester, UK., Jenner M; University Hospital Southampton NHS Foundation Trust, Southampton, UK., Hockaday A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Drayson MT; Institute of Immunology and Immunotherapy University of Birmingham, Birmingham, UK., Morris TCM; College of Myeloma, Belfast, UK., Rawstron AC; Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals Trust, Leeds, UK., Owen RG; Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals Trust, Leeds, UK.
Publikováno v:
Bone marrow transplantation [Bone Marrow Transplant] 2024 Mar; Vol. 59 (3), pp. 431-434. Date of Electronic Publication: 2024 Jan 09.
Autor:
Kaiser MF; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Hall A; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Walker K; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Sherborne A; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom., De Tute RM; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Newnham N; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Roberts S; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Ingleson E; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Bowles K; Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom., Garg M; Department of Haematology, Leicester Royal Infirmary, Leicester, United Kingdom., Lokare A; Department of Haematology, Birmingham Heartlands, Birmingham, United Kingdom., Messiou C; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Houlston RS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom., Jackson G; Department of Haematology, Newcastle University, Newcastle, United Kingdom., Cook G; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Pratt G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Owen RG; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Drayson MT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Brown SR; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Jenner MW; Department of Haematology, University Hospital Southampton, Southampton, United Kingdom.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Aug 10; Vol. 41 (23), pp. 3945-3955. Date of Electronic Publication: 2023 Jun 14.
Autor:
Yong K; Cancer Institute, University College London, London, UK; Clinical Haematology Department, University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: kwee.yong@ucl.ac.uk., Wilson W; Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK., de Tute RM; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK., Camilleri M; Cancer Institute, University College London, London, UK; Clinical Haematology Department, University College London Hospitals NHS Foundation Trust, London, UK., Ramasamy K; Department of Clinical Haematology, Oxford University Hospitals NHS Trust, Oxford, UK., Streetly M; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Sive J; Clinical Haematology Department, University College London Hospitals NHS Foundation Trust, London, UK., Bygrave CA; Department of Haematology, University Hospital of Wales, Cardiff, UK., Benjamin R; Haematology Department, Kings College Hospital, London, UK., Chapman M; Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK., Chavda SJ; Cancer Institute, University College London, London, UK., Phillips EH; Haematology Oncology Department, University of Manchester, Manchester, UK., Del Mar Cuadrado M; Cancer Institute, University College London, London, UK., Pang G; Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK., Jenner R; Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK., Dadaga T; Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK., Kamora S; Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK., Cavenagh J; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK., Clifton-Hadley L; Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK., Owen RG; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK., Popat R; Clinical Haematology Department, University College London Hospitals NHS Foundation Trust, London, UK.
Publikováno v:
The Lancet. Haematology [Lancet Haematol] 2023 Feb; Vol. 10 (2), pp. e93-e106. Date of Electronic Publication: 2022 Dec 15.
Autor:
de Tute RM; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Pawlyn C; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Cairns DA; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, NY., Menzies T; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Rawstron A; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Jones JR; Eastbourne District General Hospital, Eastbourne, United Kingdom.; Brighton and Sussex Medical School, University of Sussex, Sussex, United Kingdom.; Kings College Hospital, NHS Foundation Trust, London, United Kingdom., Hockaday A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Henderson R; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Cook G; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.; Kings College Hospital, NHS Foundation Trust, London, United Kingdom., Drayson MT; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Jenner MW; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Kaiser MF; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Gregory WM; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Morgan GJ; Perlmutter Cancer Center, NYU Langone Health, New York, NY., Jackson GH; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom., Owen RG; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Sep 01; Vol. 40 (25), pp. 2889-2900. Date of Electronic Publication: 2022 Apr 04.
Autor:
Yong KL; Cancer Institute, University College London, London. kwee.yong@ucl.ac.uk., Hinsley S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds., Auner HW; Department of Immunology and Inflammation and The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London., Bygrave C; Cardiff and Vale University Health Board, Cardiff., Kaiser MF; The Institute of Cancer Research, London, UK and The Royal Marsden Hospital NHS Foundation Trust, London., Ramasamy K; Department of Clinical Haematology, Oxford University Hospitals NHS Trust, Oxford., De Tute RM; Department of Clinical Haematology, Leeds Teaching Hospitals NHS Trust, Leeds., Sherratt D; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds., Flanagan L; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds., Garg M; Department of Haematology, University Hospitals of Leicester NHS Trust, Leicester., Hawkins S; The Clatterbridge Cancer Centre, Liverpool., Williams C; Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham., Cavenagh J; Department of Haematology, St Bartholomew's Hospital, London., Rabin NK; Department of Haematology, University College Hospital, London., Croft J; The Institute of Cancer Research, London, UK and The Royal Marsden Hospital NHS Foundation Trust, London., Morgan G; Perlmutter Cancer Center, NYU Langone Health, New York., Davies F; Perlmutter Cancer Center, NYU Langone Health, New York., Owen RG; Haematological Malignancy Diagnostic Service (HMDS), St James's University Hospital, Leeds., Brown SR; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds.
Publikováno v:
Haematologica [Haematologica] 2021 Oct 01; Vol. 106 (10), pp. 2694-2706. Date of Electronic Publication: 2021 Oct 01.
Autor:
Poulter JA; Leeds Institute of Rheumatic and Musculoskeletal Medicine and.; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom., Collins JC; National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD., Cargo C; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, United Kingdom., De Tute RM; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, United Kingdom., Evans P; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, United Kingdom., Ospina Cardona D; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Bowen DT; Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom., Cunnington JR; Department of Rheumatology, Hull University Teaching Hospitals, Hull, United Kingdom., Baguley E; Department of Rheumatology, Hull University Teaching Hospitals, Hull, United Kingdom., Quinn M; Department of Rheumatology, York Teaching Hospital NHS Foundation Trust, York, United Kingdom; and., Green M; Department of Rheumatology, York Teaching Hospital NHS Foundation Trust, York, United Kingdom; and., McGonagle D; Leeds Institute of Rheumatic and Musculoskeletal Medicine and.; National Institute for Health Research-Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom., Beck DB; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Werner A; National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD., Savic S; Leeds Institute of Rheumatic and Musculoskeletal Medicine and.; National Institute for Health Research-Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom.
Publikováno v:
Blood [Blood] 2021 Jul 01; Vol. 137 (26), pp. 3676-3681.